Text Size

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00038636
First received: June 3, 2002
Last updated: August 13, 2006
Last verified: August 2006
History of Changes
  Purpose

The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir


Condition Intervention Phase
HIV Infections
 Drug: Lopinavir/ritonavir
Drug: Ritonavir
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by Abbott:

Primary Outcome Measures:
  • Virologic and immunologic activity evaluations include plasma HIV RNA, CD4 and CD8 cell counts

Estimated Enrollment: 36
Study Start Date: September 2000
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion:

  • HIV positive
  • Are at least 18 years old
  • Subject has not been treated for an active AIDS-defining opportunistic infection within 15 days of screening
  • HIV RNA level > 1000 copies/mL
  • Previous therapy with at least one protease inhibitor, at least one non-nucleoside reverse transcriptase inhibitor and at least one nucleoside reverse transcriptase inhibitor

Exclusion:

  • Subject is pregnant or breast-feeding
  • Subject has received an investigational drug within 30 days prior to screening
  • Have a history of pancreatitis
  • History of intolerance to ritonavir
  • Abnormal laboratory tests at screening
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00038636

Locations
United States, California
UCSD Treatment Center
San Diego, California, United States, 92103-6329
United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, North Carolina
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
France
Hopital Pitie-Salpetriere
Paris, France, 75651
Hospital Europeen Georges Pompidou
Paris, France, 75908
Spain
Hospital Clinico de Barcelona
Barcelona, Spain, 08036
Ciutat Sanitaria de Bellvitge
Barcelona, Spain, 08907
Sponsors and Collaborators
Abbott
Investigators
Study Chair: Eugene Sun, M.D. Divisional Vice President, Infectious Diseases and Virology Dept.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00038636     History of Changes
Obsolete Identifiers: NCT00006210
Other Study ID Numbers: M99-049
Study First Received: June 3, 2002
Last Updated: August 13, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by Abbott:
HIV

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Protease Inhibitors
Ritonavir
 Lopinavir
Reverse Transcriptase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Nucleic Acid Synthesis Inhibitors
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
HIV Protease Inhibitors
Anti-HIV Agents

ClinicalTrials.gov processed this record on May 23, 2013